Evaluation of The Postprandial Impact of Automated Priming Bolus for Full Closed Loop Insulin Delivery (Rocket-BPS)

The purpose of this study is to understand the impact of the automated priming boluses on the safety and feasibility of a new fully automated AP controller.

Study Overview

• Status: Completed
• Conditions: Type 1 Diabetes
• Intervention / Treatment: Device: FCL+BPS; Device: FCL

Detailed Description

Study participants will be admitted to the hotel for a 4-night study, receiving the two sessions in random order: 1) Fully control loop (FCL) with the bolus priming system (BPS) activated, 2) FCL without the BPS, with a 24-hour washout period in between. During the admission, participants will receive structured meals and have blood glucose control followed to compare time in range 70-180 mg/dL between Controller sessions. After the first 24 hour period on the first FCL approach (BPS vs. no BPS,) that the participant has been randomized to, there will be a 24 hour challenge period before shifting to the other randomized approach; during this session participants will undergo further testing of the control algorithm, including meal challenges and a high-intensity interval training bout.

• Study Type: Interventional
• Enrollment (Actual): 15
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Virginia
    • Charlottesville, Virginia, United States, 22903
      • University of Virginia Center for Diabetes Technology

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Age ≥18.0 and ≤65 years old at time of consent
2. Clinical diagnosis, based on investigator assessment, of type 1 diabetes for at least one year
3. Currently using insulin for at least six months
4. Currently using insulin pump for at least three months
5. Using insulin parameters such as carbohydrate ratio and correction factors consistently on their pump in order to dose insulin for meals or corrections
6. Current regular exercise (e.g. walk, bike, jog) and be able to participate in a high intensity interval training activity.
7. Access to internet and willingness to upload data during the study as needed
8. For females, not currently known to be pregnant or breastfeeding
9. If female and sexually active, must agree to use a form of contraception to prevent pregnancy while a participant in the study. A negative serum or urine pregnancy test will be required for all females of childbearing potential. Participants who become pregnant will be discontinued from the study. Also, participants who during the study develop and express the intention to become pregnant within the timespan of the study will be discontinued.
10. Willingness to suspend use of any personal CGM for the duration of the clinical trial once the study CGM is in use
11. Willingness to use the UVa closed-loop system throughout study admission
12. Willingness to use personal lispro (Humalog) or aspart (Novolog) during the study admission.
13. Willingness not to start any new non-insulin glucose-lowering agent during the course of the trial (including metformin/biguanides, GLP-1 receptor agonists, pramlintide, DPP-4 inhibitors, sulfonylureas and naturaceuticals)
14. Willingness to eat at least 1 g/kg of carbohydrate per day during the hotel admission
15. Willingness to reschedule if placed on oral steroids
16. An understanding and willingness to follow the protocol and signed informed consent
17. Willingness to follow COVID-19 protocols in place at the time of study.

Exclusion Criteria:

1. History of diabetic ketoacidosis (DKA) in the 6 months prior to enrollment
2. Severe hypoglycemia resulting in seizure or loss of consciousness in the 12 months prior to enrollment
3. Pregnancy or intent to become pregnant during the trial
4. Currently being treated for a seizure disorder
5. Planned surgery during study duration.
6. Treatment with meglitinides/sulfonylureas at the time of hotel study.
7. Use of metformin/biguanides, GLP-1 agonists, pramlintide, DPP-4 inhibitors, SGLT-2 inhibitors, or naturaceuticals with a change in dose in the past month.
8. Coronary artery disease or heart failure, unless written clearance is received from a cardiologist or personal health care provider allowing clearance for high-intensity interval training and documentation of a negative stress test within the year
9. History of cardiac arrhythmia (except for benign premature atrial contractions and benign premature ventricular contractions which are permitted or previous ablation of arrhythmia without recurrence which may be permitted)
10. Clinically significant electrocardiogram (ECG) at time of Screening, as interpreted by the study medical physician.

11. A known medical condition that in the judgment of the investigator might interfere with the completion of the protocol such as the following examples:

    1. Inpatient psychiatric treatment in the past 6 months
    2. Presence of a known adrenal disorder
    3. Abnormal liver function test results (Transaminase >2 times the upper limit of normal); testing required for subjects taking medications known to affect liver function or with diseases known to affect liver function
    4. Uncontrolled thyroid disease
    5. Musculoskeletal or other condition that limits participation in exercise portion of study
12. A known medical condition that in the judgment of the investigator might interfere with the completion of the protocol.
13. Positive Covid-19 test result

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Full closed-loop (FCL) with Bolus Priming System (BPS) followed by FCL without BPS; Two separate 24-hour periods during where fully closed loop (FCL) control is used with & without the Bolus Priming system (BPS) active (BPS is designed to recognize meal ingestion & deliver a quick priming dose of insulin prior to extreme blood sugar excursions.) These will be separated by a 24-hour challenge period which will involve further meal & exercise challenges. During these 24-hour periods, participants will be followed for the experimental meals as part of the Study Controller Sessions to compare blood glucose control with & without the BPS. The study meals & activities will be standardized between study sessions. During a washout period, we will test the RocketAP system in FCL with further challenges: A session of high-intensity interval training; A high-carbohydrate, high-fat meal; Ingestion of a bolus of simple sugar	Device: FCL+BPS; The automated insulin delivery system includes the Bolus Priming System, a software automatically analyzing past continuous glucose monitoring values to trigger priming insulin bolus delivery isn the suspected presence of meal like glycemic disturbances; Other Names: Full closed-loop (FCL) with Bolus Priming System; Device: FCL; The automated insulin delivery system does not include the Bolus Priming System, and therefore does not automatically command priming boluses.; Other Names: Full closed-loop (FCL) without Bolus Priming System
Active Comparator: Full closed-loop (FCL) without Bolus Priming System (BPS) followed by FCL with BPS; Two separate 24-hour periods during where fully closed loop (FCL) control is used with & without the Bolus Priming system (BPS) active (BPS is designed to recognize meal ingestion & deliver a quick priming dose of insulin prior to extreme blood sugar excursions.) These will be separated by a 24-hour challenge period which will involve further meal & exercise challenges. During these 24-hour periods, participants will be followed for the experimental meals as part of the Study Controller Sessions to compare blood glucose control with & without the BPS. The study meals & activities will be standardized between study sessions. During a washout period, we will test the RocketAP system in FCL with further challenges: A session of high-intensity interval training; A high-carbohydrate, high-fat meal; Ingestion of a bolus of simple sugar	Device: FCL+BPS; The automated insulin delivery system includes the Bolus Priming System, a software automatically analyzing past continuous glucose monitoring values to trigger priming insulin bolus delivery isn the suspected presence of meal like glycemic disturbances; Other Names: Full closed-loop (FCL) with Bolus Priming System; Device: FCL; The automated insulin delivery system does not include the Bolus Priming System, and therefore does not automatically command priming boluses.; Other Names: Full closed-loop (FCL) without Bolus Priming System

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Difference in Daytime Time-in-range	Percent of CGM values falling between 70 and 180 mg/dL during daytime (6am to midnight)	18 hours

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Difference in Overall Time-in-range	Percent of CGM values falling between 70 and 180 mg/dL	24 hours
Difference in Daytime Time-below-range	Percent of CGM values falling below 70mg/dL during daytime (6am to midnight)	18 hours
Difference in Overall Time-below-range	Percent of CGM values falling below 70mg/dL	24 hours

Collaborators and Investigators

• Sponsor: Marc Breton
• Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
• Investigators: Principal Investigator: Sue Brown, MD, University of Virginia Center for Diabetes Technology

Study record dates

Study Major Dates

• Study Start (Actual): October 20, 2022
• Primary Completion (Actual): January 13, 2023
• Study Completion (Actual): January 15, 2023

Study Registration Dates

• First Submitted: August 29, 2022
• First Submitted That Met QC Criteria: August 31, 2022
• First Posted (Actual): September 6, 2022

Study Record Updates

• Last Update Posted (Actual): October 16, 2023
• Last Update Submitted That Met QC Criteria: October 13, 2023
• Last Verified: October 1, 2023

More Information

Terms related to this study

• Keywords: Artificial Pancreas (AP); Continuous Glucose Monitor (CGM); Closed Loop Control (CLC); High-intensity interval training (HIIT); Hybrid Closed Loop (HCL); Continuous subcutaneous insulin infusion (CSII); Fully Automated Closed Loop (FCL); Bolus Priming System (BPS)
• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Immune System Diseases; Autoimmune Diseases; Endocrine System Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 1
• Other Study ID Numbers: 220261; R01DK129553 (U.S. NIH Grant/Contract)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes